As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for samples received on April 20, at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Babesia is a selective pooled NAT test, required for all blood donations collected by May 2020, in 14 States and the District of Columbia. To help you understand the requirements, CTS will host a Babesia Implementation and Review webinar on March 3, 2020 at 11:00 am CST. If you are interested in attending, please contact your Customer Service Manager for invitation details.
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...